[Cholestatic hepatitis during treatment with I.N.H. and rifampicin: arguments in favour of the hepatotoxicity of rifampicin (author's transl)].
It is generally accepted that hepatitis occurring during treatment with INH and rifampicine results from the hepatotoxicity of INH metabolites. A case is reported of cholestatic hepatitis occurring during such treatment, in which there was a previous history of an isolated hepatic affection. The administration of INH and rifampicin caused cholestasis alone, which reoccurred after rifampicin administration only. No immuno-allergic phenomenon has been shown to be involved in rifampicin toxicity. This observation suggests that rifampicin may be hepatotoxic itself, especially in patients with previous hepatic affections.
D000368:Aged; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D002779:Cholestasis / Q000139:chemically induced*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage / Q000009:adverse effects*; D008099:Liver / Q000187:drug effects*; D008107:Liver Diseases / Q000150:complications; D014395:Peritonitis, Tuberculous / Q000188:drug therapy; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects*
D007538:Isoniazid; D012293:Rifampin
Hépatite cholestatique au cours d'un traitement par l'I.N.H. et la rifampicine : arguments en faveur de l'hépatotoxicité de la rifampicine.